Potential predictive biomarker for response to PD-L1 checkpoint blocker found

Scientists analyzed tissue samples from patients who had -- and had not -- responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.